Table 2.
Outcome of 19 AML patients receiving clofarabine and cytosine arabinoside
| Parameters | CR | NR |
|---|---|---|
| Primary refractory (N = 4) | 2 | 2 |
| Male | 2 | 0 |
| Female | 0 | 2 |
| Age | ||
| ≤50 years | 0 | 2 |
| >50 years | 2 | 0 |
| Prior treatment regimens | ||
| ≤2 | 1 | 0 |
| >2 | 1 | 2 |
| Cytogenetic features | ||
| Adverse | 0 | 2 |
| Others | 2 | 0 |
| Dose of cytosine arabinoside | ||
| 1 g/m2 | 0 | 1 |
| 2 g/m2 | 2 | 1 |
| First relapse (N = 11) | 5 | 6 |
| Male | 3 | 1 |
| Female | 2 | 5 |
| Age | ||
| ≤50 years | 4 | 4 |
| >50 years | 1 | 2 |
| Time from relapse | ||
| ≤6 months | 2 | 5 |
| >6 months | 3 | 1 |
| Prior treatment regimens | ||
| ≤2 | 1 | 3 |
| >2 | 4 | 3 |
| Cytogenetic features | ||
| Adverse | 2 | 1 |
| Others | 3 | 5 |
| Dose of cytosine arabinoside | ||
| 1 g/m2 | 0 | 3 |
| 2 g/m2 | 5 | 3 |
| Second relapse (N = 4) | 2 | 2 |
| Male | 2 | 0 |
| Female | 0 | 2 |
| Age | ||
| ≤50 years | 2 | 1 |
| >50 years | 0 | 1 |
| Time from relapse | ||
| ≤6 months | 1 | 2 |
| >6 months | 1 | 0 |
| Prior treatment regimens | ||
| ≤2 | 1 | 0 |
| >2 | 1 | 2 |
| Cytogenetic features | ||
| Adverse | 0 | 1 |
| Others | 1 (NA in 1) | 1 |
| Dose of cytosine arabinoside | ||
| 1 g/m2 | 0 | 0 |
| 2 g/m2 | 2 | 2 |
NA not available